{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:27:58Z","timestamp":1794360478373,"version":"4.9.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to severe disability and premature death in young men. As DMD is caused by the absence of dystrophin, therapeutic development has focused on strategies to restore dystrophin expression. These include readthrough of premature stop codons, exon skipping to restore the reading frame, and gene therapy. The first two methods are mutation-specific, benefiting only subsets of patients, whereas gene therapy could treat all individuals with DMD. Immunogenicity of dystrophin may challenge these efforts. The immune system can recognize dystrophin as a neo-antigen, just as it can recognize newly arising antigens present on mutated cells. An in-depth evaluation of anti-dystrophin immune response as a factor affecting the treatment effectiveness is needed. Key questions include the underlying mechanisms of immunity induction by antigenic epitopes of the re-expressed dystrophin, the impact of such responses on the therapeutic efficacy, and the role of patient-specific risk factors, such as preimmunization due to revertant fibres, chronic muscle inflammation, pre-existing T lymphocytes reactive to dystrophin, which avoided deletion in dystrophic thymus, or antigen cross-reactivity. Patients\u2019 immune status assessment before treatment may help mitigating anti-dystrophin responses. Exploring potential therapeutic strategies to enhance treatment outcomes is also essential: Since DMD can be diagnosed at birth, early dystrophin re-expression could prevent damage and also potentially induce neonatal tolerance. In older patients, carefully managed immunosuppression and tolerogenic protocols could pave the way for more successful dystrophin replacement therapies.<\/jats:p>","DOI":"10.1038\/s41434-025-00531-y","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T19:22:03Z","timestamp":1743794523000},"page":"561-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy?"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-1654","authenticated-orcid":false,"given":"Dariusz C.","family":"G\u00f3recki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kalinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pomeroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"531_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31:332\u201341.","journal-title":"Nat Med"},{"key":"531_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJM198805263182104","volume":"318","author":"EP Hoffman","year":"1988","unstructured":"Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loire JD, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne\u2019s or Becker\u2019s muscular dystrophy. N Engl J Med. 1988;318:1363\u20138.","journal-title":"N Engl J Med"},{"key":"531_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/266472a0","volume":"266","author":"AEH Emery","year":"1977","unstructured":"Emery AEH. Muscle histology and creatine kinase levels in the foetus in Duchenne muscular dystrophy. Nature 1977;266:472\u20133.","journal-title":"Nature"},{"key":"531_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jcsm.12665","volume":"12","author":"V Mournetas","year":"2021","unstructured":"Mournetas V, Massourid\u00e8s E, Dupont JB, Kornobis E, Polv\u00e8che H, Jarrige M, et al. Myogenesis modelled by human pluripotent stem cells: a multi\u2010omic study of Duchenne myopathy early onset. J Cachexia Sarcopenia Muscle. 2021;12:209\u201332.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"531_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/dmcn.14623","volume":"2","author":"P van Dommelen","year":"2020","unstructured":"van Dommelen P, van Dijk O, de Wilde JA, Verkerk PH. Early developmental milestones in Duchenne muscular dystrophy. Dev ed Child Neurol 2020;2:1198\u2013204.","journal-title":"Dev ed Child Neurol"},{"key":"531_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, Van Zwet E, Pogoryelova O, McMacken G, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD Global Database. J Neuromuscul Dis. 2017;4:293\u2013306.","journal-title":"J Neuromuscul Dis"},{"key":"531_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","volume":"65","author":"YW Chen","year":"2005","unstructured":"Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005;65:826\u201334.","journal-title":"Neurology"},{"key":"531_CR8","first-page":"497","volume":"43","author":"S Cotton","year":"2001","unstructured":"Cotton S, Voudouris NJ, Greenwood KM. Intelligence and Duchenne muscular dystrophy: full-Scale, Verbal, and Performance intelligence quotients. Dev Med Child Neurol. 2001;43:497\u2013501.","journal-title":"Dev Med Child Neurol"},{"key":"531_CR9","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/0883073815570154","volume":"30","author":"R Banihani","year":"2015","unstructured":"Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A, et al. Cognitive and neurobehavioral profile in boys with duchenne muscular dystrophy. J Child Neurol. 2015;30:1472\u201382.","journal-title":"J Child Neurol"},{"key":"531_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","volume":"58","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Mandy WPL, Scoto M, Pane M, Deconinck N, Messina S, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016;58:77\u201384.","journal-title":"Dev Med Child Neurol"},{"key":"531_CR11","doi-asserted-by":"publisher","first-page":"e0271681","DOI":"10.1371\/journal.pone.0271681","volume":"17","author":"G Coratti","year":"2022","unstructured":"Coratti G, Lenkowicz J, Norcia G, Lucibello S, Ferraroli E, d\u2019Amico A, et al. Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy. PLoS One. 2022;17:e0271681.","journal-title":"PLoS One"},{"key":"531_CR12","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00198-022-06416-9","volume":"33","author":"K Tsaknakis","year":"2022","unstructured":"Tsaknakis K, J\u00e4ckle K, L\u00fcders KA, Lorenz HM, Braunschweig L, Hell AK. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis. Osteoporos Int. 2022;33:2011\u20138.","journal-title":"Osteoporos Int"},{"key":"531_CR13","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/jbmr.410","volume":"26","author":"A Rufo","year":"2011","unstructured":"Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, et al. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Min Res. 2011;26:1891\u2013903.","journal-title":"J Bone Min Res"},{"key":"531_CR14","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/jcsm.12914","volume":"13","author":"M Chesshyre","year":"2022","unstructured":"Chesshyre M, Ridout D, Hashimoto Y, Ookubo Y, Torelli S, Maresh K, et al. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2022;13:1360\u201372.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"531_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ajpath.2019.09.021","volume":"190","author":"CNJ Young","year":"2020","unstructured":"Young CNJ, Gosselin MRF, Rumney R, Oksiejuk A, Chira N, Bozycki L, et al. Total absence of dystrophin expression exacerbates ectopic myofiber calcification and fibrosis and alters macrophage infiltration patterns. Am J Pathol. 2020;190:190\u2013205.","journal-title":"Am J Pathol"},{"key":"531_CR16","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, B\u00f6nnemann CG, Muntoni F. Muscular dystrophies. Lancet 2019;394:2025\u201338.","journal-title":"Lancet"},{"key":"531_CR17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. 2015;5:1223\u201339.","journal-title":"Compr Physiol"},{"key":"531_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/cancers15051378","volume":"15","author":"N Alnassar","year":"2023","unstructured":"Alnassar N, Borczyk M, Tsagkogeorga G, Korostynski M, Han N, G\u00f3recki DC. Downregulation of dystrophin expression occurs across diverse tumors, correlates with the age of onset, staging and reduced survival of patients. Cancers (Basel). 2023;15:1378.","journal-title":"Cancers (Basel)"},{"key":"531_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ng.2974","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014;46:601\u20136.","journal-title":"Nat Genet"},{"key":"531_CR20","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont NA, Wang YX, Von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21:1455\u201363.","journal-title":"Nat Med"},{"key":"531_CR21","doi-asserted-by":"publisher","first-page":"e75521","DOI":"10.7554\/eLife.75521","volume":"11","author":"MRF Gosselin","year":"2022","unstructured":"Gosselin MRF, Mournetas V, Borczyk M, Verma S, Occhipinti A, R\u00f3g J, et al. Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts. Elife 2022;11:e75521.","journal-title":"Elife"},{"key":"531_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep12831","volume":"5","author":"E Shoji","year":"2015","unstructured":"Shoji E, Sakurai H, Nishino T, Nakahata T, Heike T, Awaya T, et al. Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci Rep. 2015;5:12831.","journal-title":"Sci Rep."},{"key":"531_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-11-345","volume":"11","author":"MM Ghahramani Seno","year":"2010","unstructured":"Ghahramani Seno MM, Trollet C, Athanasopoulos T, Graham IR, Hu P, Dickson G. Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization. BMC Genomics. 2010;11:345.","journal-title":"BMC Genomics"},{"key":"531_CR24","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1073\/pnas.1605265113","volume":"113","author":"EP Rader","year":"2016","unstructured":"Rader EP, Turk R, Willer T, Beltr\u00e1n D, Inamori KI, Peterson TA, et al. Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle. Proc Natl Acad Sci USA. 2016;113:10992\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"531_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229\u201336.","journal-title":"Nature."},{"key":"531_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22:917\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"531_CR27","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s00415-023-11687-1","volume":"270","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Osorio AN, Muntoni F, Buccella F, Desguerre I, Kirschner J, et al. Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis. J Neurol. 2023;270:3896\u2013913.","journal-title":"J Neurol"},{"key":"531_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/pharmaceutics15030778","volume":"15","author":"H Wilton-Clark","year":"2023","unstructured":"Wilton-Clark H, Yokota T. Recent trends in antisense therapies for Duchenne muscular dystrophy. Pharmaceutics. 2023;15:778.","journal-title":"Pharmaceutics."},{"key":"531_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial. Muscle Nerve. 2024;69:93\u20138.","journal-title":"Muscle Nerve"},{"key":"531_CR30","doi-asserted-by":"publisher","first-page":"e21628","DOI":"10.1096\/fj.202100057RR","volume":"35","author":"X Chu","year":"2021","unstructured":"Chu X, Li J, Qiao C, Wang J, Wang Y, Jiang XC, et al. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function. FASEB J. 2021;35:e21628.","journal-title":"FASEB J"},{"key":"531_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","volume":"632","author":"H Tasfaout","year":"2024","unstructured":"Tasfaout H, Halbert CL, McMillen TS, Allen JM, Reyes TR, Flint GV, et al. Split intein-mediated protein trans-splicing to express large dystrophins. Nature 2024;632:192\u2013200.","journal-title":"Nature"},{"key":"531_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/sj.gt.3301261","volume":"7","author":"S Braun","year":"2000","unstructured":"Braun S, Thioudellet C, Rodriguez P, Ali-Hadji D, Perraud F, Accart N, et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther. 2000;7:1447\u201357.","journal-title":"Gene Ther"},{"key":"531_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/path.5263","volume":"248","author":"MC Vila","year":"2019","unstructured":"Vila MC, Novak JS, Benny Klimek M, Li N, Morales M, Fritz AG, et al. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice. J Pathol. 2019;248:339\u201351.","journal-title":"J Pathol"},{"key":"531_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1006\/mthe.2002.0675","volume":"6","author":"SC Gilchrist","year":"2002","unstructured":"Gilchrist SC, Ontell MP, Kochanek S, Clemens PR. Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Mol Ther. 2002;6:359\u201368.","journal-title":"Mol Ther"},{"key":"531_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/sj.gt.3302984","volume":"14","author":"K Yuasa","year":"2007","unstructured":"Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, Nakamura A, et al. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther. 2007;14:1249\u201360.","journal-title":"Gene Ther"},{"key":"531_CR36","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne\u2019s muscular dystophy. N Engl J Med. 2010;363:1429\u201337.","journal-title":"N Engl J Med"},{"key":"531_CR37","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG B\u00f6nnemann","year":"2023","unstructured":"B\u00f6nnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;388:2294\u20136.","journal-title":"N Engl J Med"},{"key":"531_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016;53:145\u201351.","journal-title":"J Med Genet"},{"key":"531_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84077-w","volume":"15","author":"RA Potter","year":"2025","unstructured":"Potter RA, Moeller IH, Khan S, Haegel H, Hollenstein A, Steiner G, et al. Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. Sci Rep. 2025;15:4.","journal-title":"Sci Rep."},{"key":"531_CR40","doi-asserted-by":"publisher","first-page":"e0135189","DOI":"10.1371\/journal.pone.0135189","volume":"10","author":"J Juan-Mateu","year":"2015","unstructured":"Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, Baena M, Verdura E, Nascimento A, et al. DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations. PLoS One. 2015;10:e0135189.","journal-title":"PLoS One"},{"key":"531_CR41","doi-asserted-by":"publisher","first-page":"15664","DOI":"10.1073\/pnas.1910456117","volume":"117","author":"R Garc\u00eda-Rodr\u00edguez","year":"2020","unstructured":"Garc\u00eda-Rodr\u00edguez R, Hiller M, Jim\u00e9nez-racia L, van der Pal Z, Balog J, Adamzek K, et al. Premature termination codons in the DMD gene cause reduced local mRNA synthesis. Proc Natl Acad Sci USA. 2020;117:15664\u20136464.","journal-title":"Proc Natl Acad Sci USA"},{"key":"531_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.22024","volume":"67","author":"V Malik","year":"2010","unstructured":"Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol. 2010;67:771\u201380.","journal-title":"Ann Neurol"},{"key":"531_CR43","doi-asserted-by":"publisher","first-page":"E9182","DOI":"10.1073\/pnas.1808648115","volume":"115","author":"PP Ho","year":"2018","unstructured":"Ho PP, Lahy LJ, Mourkioti F, Kraft PE, Filareto A, Brandt M, et al. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. Proc Natl Acad Sci USA. 2018;115:E9182\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"531_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/hum.2022.166","volume":"34","author":"K Anthony","year":"2022","unstructured":"Anthony K, Ala P, Catapano F, Meng J, Domingos J, Perry M, et al. T cell responses to dystrophin in a natural history study of Duchenne muscular dystrophy. Hum Gene Ther. 2022;34:439\u201348.","journal-title":"Hum Gene Ther"},{"key":"531_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.nmd.2010.03.007","volume":"20","author":"V Arechavala-Gomeza","year":"2010","unstructured":"Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, Main M, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord. 2010;20:295\u2013301.","journal-title":"Neuromuscul Disord"},{"key":"531_CR46","doi-asserted-by":"publisher","first-page":"e72147","DOI":"10.1371\/journal.pone.0072147","volume":"8","author":"SR Pigozzo","year":"2013","unstructured":"Pigozzo SR, Da Re L, Romualdi C, Mazzara PG, Galletta E, Fletcher S, et al. Revertant fibers in the mdx murine model of duchenne muscular dystrophy: an age- and muscle-related reappraisal. PLoS One. 2013;8:e72147.","journal-title":"PLoS One"},{"key":"531_CR47","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1242\/jcs.03000","volume":"119","author":"T Yokota","year":"2006","unstructured":"Yokota T, Lu QL, Morgan JE, Davies KE, Fisher R, Takeda S, et al. Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J Cell Sci. 2006;119:2679\u201387.","journal-title":"J Cell Sci"},{"key":"531_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fimmu.2016.00116","volume":"7","author":"H Pan","year":"2016","unstructured":"Pan H, Gazarian A, Dubernard JM, Belot A, Michallet MC, Michallet M. Transplant tolerance induction in newborn infants: mechanisms, advantages, and potential strategies. Front Immunol. 2016;7:116.","journal-title":"Front Immunol"},{"key":"531_CR49","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626\u201336.","journal-title":"Nat Rev Immunol"},{"key":"531_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1006\/mthe.2001.0496","volume":"4","author":"D Hartigan-O\u2019Connor","year":"2001","unstructured":"Hartigan-O\u2019Connor D, Kirk CJ, Crawford R, Mul\u00e9 JJ, Chamberlain JS. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther. 2001;4:525\u201333.","journal-title":"Mol Ther"},{"key":"531_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nri.2016.150","volume":"17","author":"JG Tidball","year":"2017","unstructured":"Tidball JG. Regulation of muscle growth and regeneration by the immune system. Nat Rev Immunol. 2017;17:165\u201378.","journal-title":"Nat Rev Immunol"},{"key":"531_CR52","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/febs.16693","volume":"291","author":"N Caballero-S\u00e1nchez","year":"2024","unstructured":"Caballero-S\u00e1nchez N, Alonso-Alonso S, Nagy L. Regenerative inflammation: when immune cells help to re-build tissues. FEBS J. 2024;291:1597\u2013614.","journal-title":"FEBS J"},{"key":"531_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/hmg\/11.3.263","volume":"11","author":"D Porter","year":"2002","unstructured":"Porter D, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002;11:263\u201372.","journal-title":"Hum Mol Genet"},{"key":"531_CR54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1126\/scitranslmed.aaa7322","volume":"7","author":"AS Rosenberg","year":"2015","unstructured":"Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7:299.","journal-title":"Sci Transl Med"},{"key":"531_CR55","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1113\/JP281673","volume":"600","author":"BJ Petrof","year":"2022","unstructured":"Petrof BJ. Macrophage plasticity in Duchenne muscular dystrophy: a nexus of pathological remodelling with therapeutic implications. J Physiol. 2022;600:3455\u201364.","journal-title":"J Physiol"},{"key":"531_CR56","doi-asserted-by":"publisher","first-page":"1467538","DOI":"10.1155\/2018\/1467538","volume":"2018","author":"DA Cronkite","year":"2018","unstructured":"Cronkite DA, Strutt TM. The regulation of inflammation by innate and adaptive lymphocytes. J Immunol Res. 2018;2018:1467538.","journal-title":"J Immunol Res"},{"key":"531_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-200556","volume":"8","author":"M Quattrocelli","year":"2021","unstructured":"Quattrocelli M, Zelikovich AS, Salamone IM, Fischer JA, McNally EM. Mechanisms and clinical applications of glucocorticoid steroids in muscular dystrophy. J Neuromuscul Dis. 2021;8:39\u201352.","journal-title":"J Neuromuscul Dis"},{"key":"531_CR58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2613.2006.00470.x","volume":"87","author":"MR Hussein","year":"2006","unstructured":"Hussein MR, Hamed SA, Mostafa MG, Abu-Dief EE, Kamel NF, Kandil MR. The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol. 2006;87:451\u201361.","journal-title":"Int J Exp Pathol"},{"key":"531_CR59","doi-asserted-by":"publisher","first-page":"e31937","DOI":"10.1371\/journal.pone.0031937","volume":"7","author":"M van Putten","year":"2012","unstructured":"van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M, et al. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One. 2012;7:e31937.","journal-title":"PLoS One"},{"key":"531_CR60","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/21645515.2018.1527496","volume":"15","author":"R Billeskov","year":"2019","unstructured":"Billeskov R, Beikzadeh B, Berzofsky JA. The effect of antigen dose on T cell-targeting vaccine outcome. Hum Vaccin Immunother. 2019;15:407\u201311.","journal-title":"Hum Vaccin Immunother"},{"key":"531_CR61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirle","year":"2020","unstructured":"Shirle JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28:709\u201322.","journal-title":"Mol Ther"},{"key":"531_CR62","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi F, Liu YL, Dobrzynski E, Kaufhld A, Liu JH, Wang Y, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111:1347\u201356.","journal-title":"J Clin Invest"},{"key":"531_CR63","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/215744a0","volume":"215","author":"HM Cantor","year":"1967","unstructured":"Cantor HM, Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature. 1967;215:744\u20135.","journal-title":"Nature."},{"key":"531_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.immuni.2023.12.005","volume":"57","author":"SJCFM Moorlag","year":"2024","unstructured":"Moorlag SJCFM, Folkman L, Ter Horst R, Krausgruber T, Barreca D, Schuster LC, et al. Multi-omics analysis of innate and adaptive responses to BCG vaccination reveals epigenetic cell states that predict trained immunity. Immunity. 2024;57:171\u201387.e14.","journal-title":"Immunity."},{"key":"531_CR65","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","volume":"125","author":"DD Chaplin","year":"2010","unstructured":"Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125:S3\u201323.","journal-title":"J Allergy Clin Immunol"},{"key":"531_CR66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/hum.2013.092","volume":"24","author":"KM Flanigan","year":"2013","unstructured":"Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther. 2013;24:797\u2013806.","journal-title":"Hum Gene Ther"},{"key":"531_CR67","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/35100573","volume":"1","author":"MJ Shlomchik","year":"2001","unstructured":"Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147\u201353.","journal-title":"Nat Rev Immunol"},{"key":"531_CR68","first-page":"1","volume":"266","author":"RA Flavell","year":"2002","unstructured":"Flavell RA. The relationship of inflammation and initiation of autoimmune disease: Role of TNF super family members. Curr Top Microbiol Immunol. 2002;266:1\u20139.","journal-title":"Curr Top Microbiol Immunol"},{"key":"531_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000060550","volume":"5","author":"TT Chang","year":"2002","unstructured":"Chang TT, Kuchroo VK, Sharpe AH. Role of the B7-CD28\/CTLA-4 pathway in autoimmune disease. Curr Dir Autoimmun. 2002;5:113\u201330.","journal-title":"Curr Dir Autoimmun"},{"key":"531_CR70","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.4049\/jimmunol.0900448","volume":"184","author":"CS Abdul-Alim","year":"2010","unstructured":"Abdul-Alim CS, Li Y, Yee C. Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol. 2010;184:6514\u201321.","journal-title":"J Immunol"},{"key":"531_CR71","doi-asserted-by":"publisher","first-page":"1345037","DOI":"10.3389\/fimmu.2024.1345037","volume":"15","author":"S Yamasaki","year":"2024","unstructured":"Yamasaki S, Shimizu K, Fujii SI. Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ. Front Immunol. 2024;15:1345037.","journal-title":"Front Immunol"},{"key":"531_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22305-x","volume":"12","author":"A Farini","year":"2021","unstructured":"Farini A, Sitzia C, Villa C, Cassani B, Tripodi L, Legato M, et al. Defective dystrophic thymus determines degenerative changes in skeletal muscle. Nat Commun. 2021;12:2099.","journal-title":"Nat Commun"},{"key":"531_CR73","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.jbc.2021.101516","volume":"298","author":"YY Zheng","year":"2022","unstructured":"Zheng YY, Wang Y, Chen X, Wei LS, Wang H, Tao T, et al. The thymus regulates skeletal muscle regeneration by directly promoting satellite cell expansion. J Biol Chem. 2022;298:101516.","journal-title":"J Biol Chem"},{"key":"531_CR74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1006\/clim.2000.4966","volume":"98","author":"MJ Spencer","year":"2001","unstructured":"Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 2001;98:235\u201343.","journal-title":"Clin Immunol"},{"key":"531_CR75","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/labinvest.3780092","volume":"80","author":"J Morrison","year":"2000","unstructured":"Morrison J, Lu QL, Pastoret C, Partridge T, Bou-Gharios G. T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest. 2000;80:881\u201391.","journal-title":"Lab Invest"},{"key":"531_CR76","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.4049\/jimmunol.153.10.4798","volume":"153","author":"E Gussoni","year":"1994","unstructured":"Gussoni E, Pavlath GK, Miller RG, Panzara MA, Powell M, Blau HM, et al. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol. 1994;153:4798\u2013805.","journal-title":"J Immunol"},{"key":"531_CR77","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1172\/JCI119464","volume":"99","author":"MJ Spencer","year":"1997","unstructured":"Spencer MJ, Walsh CM, Dorshkind KA, Rodriguez EM, Tidball JG. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest. 1997;99:2745\u2013751.","journal-title":"J Clin Invest"},{"key":"531_CR78","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/biomedicines10030535","volume":"10","author":"CA Coles","year":"2022","unstructured":"Coles CA, Woodcock I, Pellicci DG, Houweling PJ. A spotlight on T lymphocytes in Duchenne muscular dystrophy-not just a muscle defect. Biomedicines 2022;10:535.","journal-title":"Biomedicines"},{"key":"531_CR79","doi-asserted-by":"publisher","first-page":"C886","DOI":"10.1152\/ajpcell.1994.267.4.C886","volume":"267","author":"D Ferrari","year":"1994","unstructured":"Ferrari D, Munerati M, Melchiorri L, Hanau S, Di Virgilio F, Baricordi OR. Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients. Am J Physiol. 1994;267:C886\u201392.","journal-title":"Am J Physiol"},{"key":"531_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","volume":"22","author":"PS Kim","year":"2010","unstructured":"Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22:223\u201330.","journal-title":"Curr Opin Immunol"},{"key":"531_CR81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/QCO.0000000000000074","volume":"27","author":"Y Wang","year":"2014","unstructured":"Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Curr Opin Infect Dis. 2014;27:303\u20138.","journal-title":"Curr Opin Infect Dis"},{"key":"531_CR82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaut.2017.07.010","volume":"85","author":"A Sica","year":"2017","unstructured":"Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017;85:117\u201325.","journal-title":"J Autoimmun"},{"key":"531_CR83","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.coi.2004.01.010","volume":"16","author":"M Terabe","year":"2004","unstructured":"Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004;16:157\u201362.","journal-title":"Curr Opin Immunol"},{"key":"531_CR84","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00262-016-1820-y","volume":"65","author":"J Zong","year":"2016","unstructured":"Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother. 2016;65:821\u201333.","journal-title":"Cancer Immunol Immunother"},{"key":"531_CR85","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri1569","volume":"5","author":"P Kalinski","year":"2005","unstructured":"Kalinski P, Moser M. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat Rev Immunol. 2005;5:251\u201360.","journal-title":"Nat Rev Immunol"},{"key":"531_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22033-2","volume":"12","author":"K Alicea-Torres","year":"2021","unstructured":"Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, et al. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021;12:1717.","journal-title":"Nat Commun"},{"key":"531_CR87","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10555-006-9002-6","volume":"25","author":"S Kusmartsev","year":"2006","unstructured":"Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 2006;25:323\u201331.","journal-title":"Cancer Metastasis Rev"},{"key":"531_CR88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/08820139.2012.695417","volume":"41","author":"N Obermajer","year":"2012","unstructured":"Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest. 2012;41:635\u201357.","journal-title":"Immunol Invest"},{"key":"531_CR89","first-page":"303","volume":"4","author":"JL Wong","year":"2016","unstructured":"Wong JL, Oberajer N, Odunsi K, Edwards RP, Kalinski P. Synergistic COX2 induction by IFN\u03b3 and TNF\u03b1 self-limits type-1 immunity in the human tumor microenvironment. Cancer. Immunol Res. 2016;4:303\u201311.","journal-title":"Immunol Res"},{"key":"531_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1101029","volume":"188","author":"P Kalinski","year":"2012","unstructured":"Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188:21\u20138.","journal-title":"J Immunol"},{"key":"531_CR91","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4161\/onci.19681","volume":"1","author":"N Obermajer","year":"2012","unstructured":"Obermajer N, Kalinski P. Key role of the positive feedback between PGE2 and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology 2012;1:762\u201364.","journal-title":"Oncoimmunology"},{"key":"531_CR92","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.20050128","volume":"202","author":"RB Mailliard","year":"2005","unstructured":"Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, et al. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med. 2005;202:941\u201353.","journal-title":"J Exp Med"},{"key":"531_CR93","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1158\/0008-5472.CAN-11-4136","volume":"72","author":"R Muthuswamy","year":"2012","unstructured":"Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, et al. NF-\u03baB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012;72:3735\u201343.","journal-title":"Cancer Res"},{"key":"531_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1309\/4EJ9KL7CGDENVVLE","volume":"124","author":"J Wenzel","year":"2005","unstructured":"Wenzel J, Bekisch B, Uerlich M, Haller O, Bieber T, T\u00fcting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol. 2005;124:37\u201348.","journal-title":"Am J Clin Pathol"},{"key":"531_CR95","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/CJI.0b013e31820b370b","volume":"34","author":"JL Wong","year":"2011","unstructured":"Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, et al. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011;34:270\u20138.","journal-title":"J Immunother"},{"key":"531_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-67577-0_1","volume":"1036","author":"P Kalinski","year":"2017","unstructured":"Kalinski P, Talmadge JE. Tumor immuno-environment in cancer progression and therapy. Adv Exp Med Biol. 2017;1036:1\u201318.","journal-title":"Adv Exp Med Biol"},{"key":"531_CR97","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.18632\/oncotarget.2998","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqu\u00e9 A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget 2014;5:12472\u2013508.","journal-title":"Oncotarget"},{"key":"531_CR98","doi-asserted-by":"publisher","first-page":"S325","DOI":"10.3233\/JND-210706","volume":"8","author":"N Li","year":"2021","unstructured":"Li N, Parkes JE, Spathis R, Morales M, McDonald J, Kendra RM, et al. The effect of immunomodulatory treatments on anti-dystrophin immune response after AAV gene therapy in dystrophin deficient mdx mice. J Neuromuscul Dis. 2021;8:S325\u201340.","journal-title":"J Neuromuscul Dis"},{"key":"531_CR99","doi-asserted-by":"publisher","first-page":"810798","DOI":"10.3389\/fimmu.2022.810798","volume":"13","author":"BM Hall","year":"2022","unstructured":"Hall BM, Verma ND, Tran GT, Hodgkinson SJ. Transplant tolerance, not only clonal deletion. Front Immunol. 2022;13:810798.","journal-title":"Front Immunol"},{"key":"531_CR100","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","volume":"24","author":"JE Kenison","year":"2024","unstructured":"Kenison JE, Stevens NA, Quintana FJ. Therapeutic induction of antigen-specific immune tolerance. Nat Rev Immunol. 2024;24:338\u201357.","journal-title":"Nat Rev Immunol"},{"key":"531_CR101","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G. Gene therapy for duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S303\u201316.","journal-title":"J Neuromuscul Dis"},{"key":"531_CR102","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.omtm.2021.02.003","volume":"20","author":"G Gernoux","year":"2021","unstructured":"Gernoux G, Guilbaud M, Devaux M, Journou M, Pichard V, Jaulin N, et al. AAV8 locoregional delivery induces long-term expression of an immunogenic transgene in macaques despite persisting local inflammation. Mol Ther Methods Clin Dev. 2021;20:660\u201374.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"531_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.","journal-title":"Nat Commun"},{"key":"531_CR104","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1097\/TP.0b013e31817726bc","volume":"85","author":"G Camirand","year":"2008","unstructured":"Camirand G, St\u00e9phan L, Rousseau J, Sackett MK, Caron NJ, Mills P, et al. Central tolerance to myogenic cell transplants does not include muscle neoantigens. Transplantation 2008;85:1791\u2013801.","journal-title":"Transplantation"},{"key":"531_CR105","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/gt.2016.82","volume":"24","author":"D Sharma","year":"2017","unstructured":"Sharma D, Al-Khalidi R, Edgar S, An Q, Wang Y, Young C, et al. Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles. Gene Ther. 2017;24:113\u20139.","journal-title":"Gene Ther"},{"key":"531_CR106","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3389\/fimmu.2017.01360","volume":"8","author":"AL Mellor","year":"2017","unstructured":"Mellor AL, Lemos H, Huang L. Indoleamine 2,3-dioxygenase and tolerance: where are we now? Front Immunol. 2017;8:1360.","journal-title":"Front Immunol"},{"key":"531_CR107","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","volume":"281","author":"DH Munn","year":"1998","unstructured":"Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191\u20133.","journal-title":"Science"},{"key":"531_CR108","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1073\/pnas.1113873109","volume":"109","author":"L Pilotte","year":"2012","unstructured":"Pilotte L, Larrieu P, Stroobant V, Colau D, Dolu\u0161i\u0107 E, Fr\u00e9d\u00e9rick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA. 2012;109:2497\u2013502.","journal-title":"Proc Natl Acad Sci USA"},{"key":"531_CR109","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/gt.2016.59","volume":"23","author":"D Vavrincova-Yaghi","year":"2016","unstructured":"Vavrincova-Yaghi D, Deelman L, van Goor H, Seelen M, Vavrinec P, Kema I, et al. Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction. Gene Ther. 2016;23:797\u2013806.","journal-title":"Gene Ther"},{"key":"531_CR110","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/172603a0","volume":"172","author":"RE Billingham","year":"1953","unstructured":"Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603\u20136.","journal-title":"Nature"},{"key":"531_CR111","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1111\/ajt.13278","volume":"15","author":"RA Bascom","year":"2015","unstructured":"Bascom RA, Tao KS, Tollenaar SL, West LJ. Imaging tolerance induction in the classic medawar neonatal mouse model: active roles of multiple F1-donor cell types. Am J Transpl. 2015;15:2346\u201363.","journal-title":"Am J Transpl"},{"key":"531_CR112","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/sj.mt.6300219","volume":"15","author":"DE Sabatino","year":"2007","unstructured":"Sabatino DE, MacKenzie TC, Peranteau W, Edmonson S, Campagnoli C, Liu YL, et al. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. Mol Ther. 2007;15:1677\u201385.","journal-title":"Mol Ther"},{"key":"531_CR113","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/mt.2015.5","volume":"23","author":"H Hayashita-Kinoh","year":"2015","unstructured":"Hayashita-Kinoh H, Yugeta N, Okada H, Nitahara-Kasahara Y, Chiyo T, Okada T, et al. Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther. 2015;23:627\u201337.","journal-title":"Mol Ther"},{"key":"531_CR114","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mt.2015.99","volume":"23","author":"C Hinderer","year":"2015","unstructured":"Hinderer C, Bell P, Louboutin JP, Zhu Y, Yu H, Lin G, et al. Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates. Mol Ther. 2015;23:1298\u2013307.","journal-title":"Mol Ther"},{"key":"531_CR115","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1073\/pnas.1015571108","volume":"108","author":"C Hu","year":"2011","unstructured":"Hu C, Cela RG, Suzuki M, Lee B, Lipshutz GS. Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci USA. 2011;108:2082\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"531_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1122","volume":"12","author":"DC G\u00f3recki","year":"2022","unstructured":"G\u00f3recki DC. Dystrophin immunogenicity and requirement in myogenic cells: Paradigm shift in gene therapy for DMD. Clin Transl Med. 2022;12:e1122.","journal-title":"Clin Transl Med"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00531-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00531-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00531-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:03:37Z","timestamp":1760375017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00531-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00531-y","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}